PMEL 17 is a melanosome specific antigen, also is designed as HMB45 or gp100. It plays a central role in the biogenesis of melanosomes, involved in the maturation of melanosomes from stage I to II. The transition from stage I melanosomes to stage II melanosomes involves an elongation of the vesicle, and the appearance within of distinct fibrillar structures.
Specifications
Catalog No.
BX50026
Clone No.
BP6031
Application
IHC-P
Subcellular location
Cytoplasm
Control
Melanoma
Recommended method
HIER
Volume
100μl/vial, 1ml/vial
Dilution
1:100-1:200
Immunogen
Synthetic peptide corresponding to PMEL 17 residues within aa561‐661 of PMEL 17 was used as an immunogen.
Reference
1.Rothberg BE, et.al, Mod Pathol. 2008 Sep;21(9):1121-9.
2.Wagner SN, et.al, Cancer Immunol Immunother. 1997 Jun;44(4):239-47.